Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-07-30

FDA Approved: DIPENTUM — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

The FDA approved a supplemental application for Dipentum (olsalazine sodium) submitted by Viatris Specialty LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DIPENTUM (olsalazine sodium)

Snippet

SUPPL AP for DIPENTUM (OLSALAZINE SODIUM)